![\"130122_7\"](\"https:\/\/www.hcfm.jp\/journal\/wp-content\/uploads\/2015\/08\/130122_7.gif\")
<\/a><\/p>\n\u3010\u958b\u50ac\u65e5\u3011
\n2012\u5e7411\u67087\u65e5<\/p>\n","protected":false},"excerpt":{"rendered":"
\u3010\u6587\u732e\u540d\u3011
\nRelapse Risk after Discontinuation of Risperidone in Alzheimer’s Disease
\n\u3000\u3000\u3000D.P. Devanand, et al. N Engl J Med 2012; 367:1497-1507<\/p>\n
\u3010\u8981\u7d04\u3011<\/p>\n
BACKGROUND
\n\u3000\u3000\u3000Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.\u00a0<\/p>\n
METHODS
\n\u3000\u3000\u3000Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse of psychosis or agitation.\u00a0<\/p>\n
RESULTS
\n\u3000\u3000\u3000A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily). The severity of psychosis and agitation were reduced, although there was a mild increase in extrapyramidal signs; 112 patients met the criteria for response to treatment, of whom 110 underwent randomization. In the first 16 weeks after randomization, the rate of relapse was higher in the group that received placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33% [23 of 70 in groups 1 and 2]; P=0.004; hazard ratio with placebo, 1.94; 95% confidence interval [CI], 1.09 to 3.45; P=0.02). During the next 16 weeks, the rate of relapse was higher in the group that was switched from risperidone to placebo than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15% [2 of 13 in group 1]; P=0.02; hazard ratio, 4.88; 95% CI, 1.08 to 21.98; P=0.02). The rates of adverse events and death after randomization did not differ significantly among the groups, although comparisons were based on small numbers of patients, especially during the final 16 weeks.\u00a0<\/p>\n
CONCLUSIONS
\n\u3000\u3000\u3000In patients with Alzheimer’s disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse.<\/p>\n